[Featured Stock] Canaria Bio Passes Global Phase 3 Clinical DSMB Review... Surges for 3 Consecutive Trading Days

[Asia Economy Reporter Kwon Jae-hee] Canaria Bio has been on a sharp rise for three consecutive trading days.

As of 9:58 AM on the 28th, Canaria Bio is trading at 25,500 KRW, up 8.51% from the previous trading day. During the session, it rose as high as 26,800 KRW (14.04%) before giving back some of the gains.

Canaria Bio announced on the 26th that the Oregovomab global Phase 3 clinical trial, conducted at 152 sites across 16 countries targeting ovarian cancer patients, has passed the review by the DSMB (Data Safety Monitoring Board).

This global Phase 3 clinical trial is reviewed every six months by the DSMB. The DSMB has the authority to halt the trial not only if serious safety issues arise but also if it determines that the treatment is ineffective.

According to the company, at the DSMB meeting held on the 21st, they received a recommendation to continue the trial. The next DSMB review is scheduled for March 2023. Interim results are expected to be announced in the third quarter of next year.